Business
aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology
Paper highlights the essential role that histidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states Lead
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Paper highlights the essential role that histidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states\n Lead therapeutic candidate, ATYR1923, being evaluated in a Phase 1b/2a trial in patients with pulmonary sarcoidosis SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a publication highlighting the essential role that histidyl tRNA synthetase (HARS) plays in the modulation of immune cell engagement in a broad range of disease states, including interstitial lung diseases. The paper, titled “Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses,” was published in the journal Cellular and Molecular Immunology. In mouse and rodent models of acute inflammatory disease, researchers found that HARS administration was shown to downregulate immune response. In contrast, HARS neutralization through targeting antibodies was associated with the activation of the immune system and the perpetuation of chronic and acute autoimmune diseases, including interstitial lung diseases (ILDs). aTyr’s lead therapeutic candidate, ATYR1923, is currently being evaluated in a Phase 1b/2a clinical trial as a potential treatment for patients with pulmonary sarcoidosis, an ILD characterized by the formation of granulomas, clumps of inflammatory cells in the lungs. The prognosis for patients with pulmonary sarcoidosis ranges from benign and self-limiting to chronic, debilitating disease with mortality. “These published findings strongly validate our hypothesis that the extracellular functionality of tRNA synthetases, a newly discovered area of biology, may hold the key to slowing or halting the progression of interstitial lung diseases, thereby preserving lung function and improving patient outcomes,” said Sanjay S. Shukla, MD, MS, President and Chief Executive Officer of aTyr. “We look forward to data from our ongoing clinical trial of ATYR1923 in pulmonary sarcoidosis anticipated later this year. In addition, we are working to expand our pipeline of tRNA synthetase based drug candidates targeting autoimmune disorders where novel treatment options are needed.” aTyr will provide a corporate update during its upcoming fo...